Parcion Private Wealth LLC Has $913,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Parcion Private Wealth LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 139.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,183 shares of the biopharmaceutical company’s stock after acquiring an additional 689 shares during the period. Parcion Private Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $913,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cornerstone Wealth Group LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $207,000. CWM LLC lifted its position in Regeneron Pharmaceuticals by 13.4% during the 4th quarter. CWM LLC now owns 60,569 shares of the biopharmaceutical company’s stock valued at $46,752,000 after purchasing an additional 7,163 shares during the period. Childress Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $316,000. KBC Group NV boosted its stake in shares of Regeneron Pharmaceuticals by 14.9% in the 4th quarter. KBC Group NV now owns 38,215 shares of the biopharmaceutical company’s stock valued at $29,496,000 after purchasing an additional 4,953 shares during the last quarter. Finally, Drum Hill Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $232,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $746.00 on Friday. The company has a market capitalization of $78.87 billion, a price-to-earnings ratio of 17.95, a P/E/G ratio of 2.00 and a beta of 0.40. The business’s 50-day moving average price is $766.33 and its two-hundred day moving average price is $724.12. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $12.07 earnings per share. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were given a dividend of $0.94 per share. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.05%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president directly owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This trade represents a 32.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the sale, the director owned 17,803 shares in the company, valued at $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,774 shares of company stock valued at $2,942,738 in the last ninety days. 7.02% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on REGN. Cantor Fitzgerald boosted their price target on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, March 27th. JPMorgan Chase & Co. lifted their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a research report on Monday, March 2nd. Finally, Evercore increased their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $811.96.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.